Reduced Bone Turnover in Mice Lacking the P2Y13 Receptor of ADP by Wang, N. et al.
	



	
			

	

	
				
 !

∀#∃#
%&#∋#(∀#(#)&#∗+

∀,,,,−,,,.−/./−0001#
∋
&2#3∗4	#(+

∀,,,,−,,,!−./!−!5.1+!,//1
∋

∗∀	6!7/.	

(86∗
9


∀&#!
+/1/5!−/0!:))∃,   −  ,
		;

∀/,/!/,2!,//−/, .
	
 
	<	

				

 1 
Title: Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. 1 
Short Title: Reduced bone turnover in P2Y13 KO mice 2 
Ning Wanga, Bernard Robayeb, Ankita Agrawala, Timothy M. Skerrya, Jean-Marie Boeynaemsb,c, 3 
Alison Gartlanda1 4 
aThe Mellanby Centre for Bone Research, Department of Human Metabolism, The University of 5 
Sheffield, Sheffield, UK, bInstitute of Interdiscipinary Research, IRIBHM, Université Libre de 6 
Bruxelles, Gosselies, Belgium, c Department of Medical Chemistry, Erasme Hospital, Brussels, 7 
Belgium 8 
1 Corresponding author and person to whom reprint requests should be addressed: 9 
Dr Alison Gartland,  10 
The Mellanby Centre for Bone Research  11 
Department of Human Metabolism 12 
The University of Sheffield  13 
Beech Hill Road  14 
Sheffield, S10 2RX  15 
UK  16 
Phone: (+44) 0114 226 1435 17 
Fax: (+44) 0114 271 1711 18 
Email: a.gartland@sheffield.ac.uk 19 
Key words: P2Y13 receptor, knock-out, osteoblasts, osteoclasts, OVX 20 
Funding Source: European Commission under the 7th Framework Programme (proposal #202231) 21 
performed as a collaborative project among the members of the ATPBone Consortium (Copenhagen 22 
University, University College London, University of Maastricht, University of Ferrara, University of 23 
Liverpool, University of Sheffield, and Université Libre de Bruxelles), and is a sub study under the 24 
PDLQVWXG\³)LJKWLQJRVWHRSRURVLVE\EORFNLQJQXFOHRWLGHVSXULQHUJLFVLJQDOOLQJLQERQHIRUPDWLRQ25 
DQGKRPHRVWDVLV´ 26 
Disclosure summary: 27 
All authors have nothing to disclose. 28 
 2 
Abstract: 29 
Osteoporosis is a condition of excessive and un-coupled bone turnover in which osteoclastic 30 
resorption exceeds osteoblastic bone formation, resulting in an overall net bone loss, bone fragility 31 
and morbidity. While numerous treatments have been developed to inhibit bone loss by blocking 32 
osteoclastic bone resorption, understanding of the mechanisms behind bone loss is incomplete. The 33 
purinergic signalling system is emerging to be a pivotal regulator of bone homeostasis and 34 
extracellular ADP has previously been shown to be a powerful osteolytic agent in vitro. We report 35 
here that deletion of the P2Y13 receptor, a G-protein coupled receptor for extracellular ADP, leads to a 36 
40% reduction in trabecular bone mass, 50% reduction in osteoblast and osteoclast numbers in vivo as 37 
well as activity in vitro and an overall 50% reduction in the rate of bone remodelling in mice in vivo. 38 
Down-regulation of RhoA/ROCK I signalling and a reduced ratio of RANKL/OPG observed in 39 
osteoblasts from P2Y13R-/- mice might explain this bone phenotype. Furthermore, as one of the main 40 
causes of osteoporosis in older women is lack of estrogen, we examined the effect of ovariectomy 41 
(OVX) of the P2Y13R-/- mice and found them to be protected from OVX-induced bone loss by up to 42 
65%. These data confirm a role of purinergic ADP signalling in the skeleton, whereby deletion of the 43 
receptor leads to reduced bone turnover rates which provide a protective advantage in conditions of 44 
accelerated bone turnover such as oestrogen deficiency-induced osteoporosis.  45 
Key words: P2Y13 receptor, knock-out, osteoblasts, osteoclasts, OVX 46 
47 
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Introduction 48 
The membrane-bound receptors for extracellular nucleotides known as P2 receptors can be divided 49 
into two major families based on their signal transduction mechanisms and topology. P2X receptors 50 
form a family of ligand-gated ion channels with signal transduction cascade via non-selective outward 51 
cation currents, whilst P2Y receptors form a family of G protein-coupled receptors coupled to Gq 52 
or/and Gi (1). Both osteoblasts and osteoclasts express numerous P2 receptor subtypes in a spatial and 53 
temporal manner (2). Specifically in osteoblasts, ATP and its degradation product adenine 54 
diphosphate (ADP) have been shown to modulate [Ca2+]i calcium signalling (3), increase cell 55 
proliferation (4), increase expression of Receptor Activator of NF-Nb Ligand (RANKL) (a key 56 
modulator of osteoclast formation and resorption) (5) and intriguingly, synergise with PTH to induce 57 
activation of c-fos, a key transcription factor in bone (6). This last observation suggests that ATP and 58 
P2 receptors represent a local mechanism enabling the bone remodelling induced by systemic 59 
hormones such as PTH to be confined to discrete foci. In osteoclasts, ATP appears to have both 60 
stimulatory (7, 8) and inhibitory roles via P2 receptors (9, 10), whilst ADP was shown to be a 61 
powerful osteolytic agent reportedly acting via the P2Y1 receptor (11). In vivo knockout models have 62 
offered further insights into the overall effect on bone homeostasis of the different, but highly 63 
significant effects of extracellular nucleotides. P2Y2 receptor deficient mice demonstrate a striking 64 
increase in bone mineral content, presumably related to the inhibitory effect of ATP on mineralization 65 
by osteoblasts (12). On the contrary, the P2X7 receptor deficient mice do not have an extreme skeletal 66 
phenotype (13) but exhibit site-specific alterations in bone formation and resorption (14). A recent 67 
preliminary investigation of P2Y1 receptor deficient mice revealed a reduced bone mass, confirming a 68 
role for ADP in bone homeostasis (15). 69 
 70 
In addition to the P2Y1 and P2Y12 receptor, the P2Y13 receptor, originally named GPR86 (16), has 71 
high affinity for ADP (17). The P2Y13 receptor is a Gi-coupled receptor which shows a high level of 72 
identity with P2Y12 and P2Y14 receptors, sharing 45-48% amino acid sequence identity (17). Similarly 73 
to the P2Y1 and P2Y12 receptors, P2Y13 receptors respond to ADP in the nanomolar range (18). 74 
Expression of P2Y13 receptor mRNA has been shown in abundance in the brain, spleen, lymph nodes 75 
 4 
and bone marrow, suggesting roles in nervous, haematopoietic, and immune systems. A lower level of 76 
expression is found in liver, lung, placenta, and spinal cord (17-19). Although P2Y13 receptors are 77 
detected in different tissues, the physiological function of this receptor is still unclear. Several reports 78 
suggesting a role of P2Y13 receptors are not entirely convincing due to the lack of truly selective 79 
agonists and antagonists for this receptor (20-25). Indeed Cangrelor (AR-C69931MX) behaves as a 80 
P2Y13 receptor antagonist (26) or partial agonist (27), although it was primarily described as a specific 81 
P2Y12 receptor antagonist and is currently in clinical development as an antithrombotic agent. The 82 
study of P2Y13 receptor-deficient mice (P2Y13R-/-) has so far revealed the role of this receptor in HDL 83 
cholesterol uptake by hepatocytes and reverse cholesterol transport (28, 29). In the context of bone, 84 
the expression of P2Y13 receptors in osteoblasts and osteoclasts has been recently confirmed (30, 31). 85 
Taken together with the previous reports of the powerful effect of ADP on osteoclasts, we sought to 86 
determine the consequence of P2Y13 receptor gene deletion on the bones of mice. Using micro 87 
computeU WRPRJUDSK\ȝ&7ZHVKRZWKDWWKHERQHVRIWKH3<13R-/- mice have altered bone mass, 88 
due to reduced numbers of osteoblasts and osteoclasts in the bone as shown by histology. Dynamic 89 
histomorphometry confirmed reduced mineral apposition and bone formation rates, whilst in vitro 90 
primary cell cultures were used to determine the effect of gene deletion on the formation and function 91 
of osteoblasts and osteoclasts. Finally, ovariectomy (OVX), a widely accepted model of bone changes 92 
after menopause (32), revealed that P2Y13R-/- mice were protected from OVX-induced bone loss by 93 
up to 65%. These findings confirm a role for the P2Y13 receptor in bone remodelling, offering a 94 
potential novel therapeutic target for fighting bone diseases in conditions of accelerated bone turnover 95 
such as oestrogen deficiency-induced osteoporosis.  96 
 97 
Results 98 
Reduced trabecular bone volume in P2Y13R-/- mice 99 
There was no severe or obvious gross morphological difference between the whole skeleton of 100 
P2Y13R-/- and wild type (WT) mice upon macroscopic examination or XVLQJȝ&7'PRGHOVRIWKH101 
whole tibia (Fig. 1A+RZHYHUȝ&7DQDO\VLVUHYHDOHGWKDWDOWKRXJKWKHOHQJWKRIWKHWLELDZDVnot 102 
significantly different, P2Y13R-/- mice had ~5% less total bone volume in the tibia compared with WT 103 
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(Fig. 1C, p < 0.05). Analysis of the microstructure of the bone in the tibia at a higher resolution 104 
revealed 37.5% less trabecular bone (p < 0.001)(Fig. 1D) and 37.8% fewer trabeculae in P2Y13R-/- 105 
mice compared to WT (p < 0.001) (Fig. 1E). Other typical trabecular bone parameters are summarised 106 
LQ7DEOHȝ&7DQDO\VLVRQD predominantly cortical bone region showed no significant effects on 107 
cortical bone parameters including cortical bone volume (p = 0.09), endosteal diameter (p = 0.41) and 108 
periosteal diameter (p = 0.48) (Table 1). 109 
 110 
Reduced osteoclast and osteoblast numbers in long bones of P2Y13R-/- mice 111 
Assessment of the cellular compartment of the bone by histological analysis showed that there were 112 
approximately half as many osteoclasts (p < 0.05) and osteoblasts (p < 0.05) on the surfaces of the 113 
cortical bone in P2Y13R-/- mice compared with WT controls (Fig. 2A-2D). In the trabecular region of 114 
the tibia, P2Y13R-/- mice had 22% fewer osteoblasts per mm trabecular surface compared with WT 115 
controls (p < 0.05) (Fig. 2E-2G) though no significant reduction in osteoclast numbers.  116 
 117 
P2Y13R-/- mice have reduced rates of bone formation in vivo 118 
To determine whether deletion of the P2Y13 receptor would lead to reduced remodelling, 16 week-old 119 
mice were given intraperitoneal injections of calcein (30 mg/kg) 14 days and 2 days prior to being 120 
euthanized to allow for assessment of the rate and extent of mineralization (Fig. 3A). Comparing the 121 
P2Y13R-/- with WT mice, the mineral apposition rate and bone formation rate were both significantly 122 
reduced by nearly 50% in the tibia (p < 0.0001 and p < 0.0001) (Fig. 3B+C).  123 
 124 
Loss of P2Y13R leads to reduced osteoblast function in vitro 125 
To determine whether osteoblast function is altered in P2Y13R-/- mice, primary osteoblasts were 126 
isolated and cultured in vitro. There were no significant differences in the proliferation rates of 127 
P2Y13R-/- osteoblasts compared with WT mice over a 5-day period (Fig. 4A). However, a 50% 128 
reduction in mineralization was observed in long term differentiation cultures compared to WT (p < 129 
0.0001)(Fig. 4B+C). These data confirm that P2Y13R is involved in normal osteoblast function. 130 
 131 
 6 
Loss of P2Y13R leads to reduced osteoclast formation in vitro 132 
TRAP positive osteoclasts with three or more nuclei were identified when isolated monocytes from 133 
both WT and P2Y13R-/- mice were cultured on glass coverslips in the presence of M-CSF and RANKL 134 
for 10 days (Fig. 4D, black arrows). The number of multinucleated osteoclasts formed from P2Y13R-/- 135 
mice was 50% lower when compared with WT (p < 0.0001) (Fig. 4E). To determine the effect on 136 
osteoclast function, isolated monocytes were cultured in the presence of M-CSF and RANKL for 17 137 
days on dentine disks and the number of resorbing osteoclasts (Fig 4F, black arrows) and amount of 138 
resorption were quantified (Fig 4F, white arrows). There were 47.1% fewer resorbing osteoclasts 139 
from P2Y13R-/- mice (p = 0.0004) (Fig 4G) which resulted in 66% less total resorption (p < 0.0001) 140 
(Fig. 4H). However, there was no significant difference in the amount of resorption per functional, 141 
resorbing osteoclast (p = 0.5) (Fig. 4I).  142 
 143 
Down-regulation of key regulatory genes in P2Y13R-/- mice 144 
To delineate the effect of P2ry13 gene deletion on downstream signalling pathways, a TaqMan 145 
custom array was used to analyse cDNA from primary osteoblasts and long bone marrow of both 146 
P2Y13R-/- and WT mice. Results confirmed the absence of the P2Y13 receptor mRNA in osteoblasts 147 
and bone marrow from P2Y13R-/- mice, further confirming successful deletion of the gene. The 148 
difference in expression for each target cDNA between the WT and P2Y13R-/- mice was analyzed 149 
using the CT relative quantification method (33). In primary osteoblasts, compared to WT the 150 
expression of RhoA was significantly down-regulated (0.10 fold change) and Tnfrsf11b (the gene for 151 
OPG) was up-regulated (2.25 fold change) in P2Y13R-/- mice (Fig. 4J). In bone marrow samples 152 
Mapk3 (0.02 fold change), Rock1 (0.25 fold change), RhoA (0.12 fold change), and Tnfsf11 (RANKL, 153 
0.45 fold change) were all significantly down-regulated (Fig. 4K). 154 
 155 
Estrogen deficiency-induced bone loss is attenuated in P2Y13R-/- mice 156 
Accelerated bone loss after the menopause is a primary cause of osteoporosis in women. To determine 157 
if the reduced osteoclast function seen in P2Y13R-/- mice may attenuate estrogen deficiency-induced 158 
bone loss, OVX surgery was performed on 4 month old mice. Four weeks after surgery, there was a 159 
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significant difference in the response of P2Y13R-/- mice compared to WT mice in BMD (p < 0.05) and 160 
trabecular thickness (p < 0.001). A significant loss of BMD in WT mice (p < 0.001) was observed at 4 161 
weeks compared to baseline, but not in P2Y13R-/- mice (Fig. 5A). PCT analysis of the trabecular bone 162 
structure of the tibial region demonstrated significant thinning of the individual trabeculae in WT 163 
mice at 4 weeks compared to baseline (p < 0.0001) but not in P2Y13R-/- mice (Fig. 5B). Interestingly, 164 
12 weeks after surgery the protection from OVX-induce bone loss in P2Y13R-/- mice was more 165 
apparent (p < 0.001 for both parameters compared with WT). In WT mice, BMD and trabecular 166 
thickness were still reduced compared with baseline (Fig. 5A, p < 0.05 and Fig. 5B p < 0.0001 167 
respectively) whereas the P2Y13R-/- mice showed an increase in both BMD (p < 0.05) and trabecular 168 
thickness compared with baseline levels (Fig. 5A and B respectively).  169 
 170 
171 
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Discussion 172 
The P2Y13 receptor is widely distributed in different tissues and cell types, including osteoclasts and 173 
osteoblasts (30, 31). Given the emerging important role of the purinergic signalling pathway in the 174 
bone microenvironment and bone remodelling, we wanted to investigate the consequence of P2Y13 175 
receptor deletion on the skeleton. Deletion of P2Y13 receptor had no effect on the gross physiology of 176 
the mice, which were healthy and fertile. When examining the bone using ȝ&7DQDO\VLVZH IRXQG177 
that the P2Y13R-/- mice had less bone volume in the whole tibia although the overall length was 178 
XQFKDQJHG $ PRUH GHWDLOHG DQDO\VLV XVLQJ KLJK UHVROXWLRQ ȝ&7 VFDQ ZDV SHUIRUPHG WR GHWHUPLQH179 
which bone compartment was the source of the observed reduction in bone. Data obtained from the 180 
proximal tibia revealed that the P2Y13R-/- mice had almost 40% less trabecular bone and trabecular 181 
number. The P2Y13R-/- mice also had significantly higher trabecular pattern factor and structural 182 
model index, which indicates a less well-connected and more rod-like structured trabecular bone, in 183 
contrast to the well connected and flat structure typically seen in normal healthy animals (34, 35). 184 
There were no significant changes in any of the relevant indices for cortical bone.  185 
 186 
To investigate further the observed bone phenotype, histomorphometric analysis demonstrated that 187 
the P2Y13R-/- mice have half the number of osteoclasts and osteoblasts per unit of bone on the 188 
endocortical bone surface, whilst in the trabecular bone only a reduction in osteoblast numbers was 189 
observed. This imbalance in osteoblast to osteoclast numbers on the trabecular bone surface may 190 
explain the loss of trabecular bone in this region, whilst the equal reduction of both osteoblasts and 191 
osteoclasts on the cortical surface would lead to no net loss of bone. In vitro primary bone marrow 192 
cell cultures confirmed that deletion of the P2Y13 receptor significantly reduced the capacity of bone 193 
marrow cells to form multinuclear, functional osteoclasts. This led to the significant decrease in total 194 
resorption observed, whereas the amount of resorption per osteoclast was not different from that of 195 
osteoclasts derived from WT bone marrow. Interestingly, primary osteoblast cultures demonstrated 196 
that the cells from P2Y13R-/- mice had reduced function, leading to a 50% decrease in mineralization. 197 
These in vitro results are consistent with the 50% decrease in bone apposition rate and bone formation 198 
rate detected in P2Y13R-/- mice using dynamic histomorphometry. Coupled with the reduction in the 199 
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number of osteoclasts this would result in an overall reduced bone remodelling rate, especially the 200 
bone formation rate, in 4 month old P2Y13R-/- mice. Due to the relatively higher turnover activity in 201 
trabecular bone than in cortical bone (36), fewer functional osteoblasts and a lower bone formation 202 
rate will have affected trabecular bone to a greater extent than cortical bone.  203 
 204 
Data obtained from the TaqMan custom array analysis provide possible explanations at the molecular 205 
level for the observed effect of P2Y13 receptor deletion on osteoblasts and osteoclasts. The down-206 
regulation of the expression of RhoA was found in both primary P2Y13R-/- osteoblasts and bone 207 
marrow. There is evidence that the P2Y13R is upstream of the RhoA/ROCK I signalling controlling 208 
HDL endocytosis in human hepatocytes (37). Our data indicate that in addition to this acute activation 209 
of the RhoA pathway, the P2Y13 receptor would also control the level of RhoA and ROCK1. 210 
Inhibition of RhoA/ROCK I signalling will reduce extracellular signal-regulated kinase (ERK) 211 
activity, diminish RUNX2 activity, and alter ALP activity in osteoblasts (38). Down regulation of 212 
ERK signalling via RhoA/ROCK I signalling in osteoclasts has previously been shown to impair 213 
survival and induce apoptosis in osteoclasts by affecting the formation of a ruffled border and the 214 
maintenance of cell polarity (39, 40). Interestingly, mRNA of Mapk3 was decreased in P2Y13R-/- bone 215 
marrow. Therefore, the deletion of P2Y13R may lead to the down regulation of RhoA/ROCK I 216 
signalling, which in turn affects the downstream ERK-MAPK signalling causing reduced function and 217 
differentiation of bone cells, particularly osteoblasts. The other interesting finding with the TaqMan 218 
analysis was the up-regulation of Tnfrsf11b (osteoprotegerin, OPG) in the P2Y13R-/- osteoblasts and 219 
the down-regulation of Tnfsf11 (RANKL) in P2Y13R-/- mice bone marrow. These gene expression 220 
alterations would indicate an overall reduced ratio of RANKL/OPG and hence negative regulation of 221 
osteoclastogenesis, which may explain the phenomenon of reduced osteoclast formation observed in 222 
P2Y13R-/- mice both in vivo and in vitro. 223 
 224 
Osteoporosis is a condition in which there is over-activated bone turnover and in which osteoclast 225 
resorption exceeds osteoblastic bone formation leading to an overall net bone loss and bone fragility 226 
(41, 42). Bone loss accelerates in older women due to the menopause because estrogen withdrawal 227 
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increases the rate of bone remodelling - coupled with negative bone balance this produces bone loss 228 
and trabecular thinning (43). To investigate the pharmaceutical potential of lower bone turnover 229 
activities induced by the deletion of P2Y13R, both P2Y13R-/- and WT mice were ovariectomized to 230 
examine the bone changes under estrogen deficiency-induced osteoporosis. Four weeks after the OVX 231 
surgery, P2Y13R-/- mice showed no significant loss of BMD, and even showed increased BMD 12-232 
weeks after surgery. The observation that the P2Y13R-/- mice have an attenuated response to estrogen 233 
deficiency-induced bone loss highlights this receptor as a possible new therapeutic target for 234 
osteoporosis. This is timely given the growing concern over the possible association of atypical 235 
fractures of the femur with long-term use of bisphosphonates (44). Bisphosphonates work by 236 
inhibiting the catabolic actions of osteoclasts leading to an overall suppression of bone turnover. Long 237 
term suppression of bone turnover may lead to the accumulation of microdamage in bone because of a 238 
failure to efficiently remove cracks which will ultimately lead to fracture of the bone (45). Targeting 239 
the P2Y13R may provide an alternative treatment which slows down the accelerated bone loss 240 
observed in post-menopausal women whilst maintaining turnover activities at a reduced rate to ensure 241 
repair of microdamage. 242 
 243 
In conclusion, this is the first detailed study to examine the role of P2Y13 receptor in bone homeostasis 244 
both in vivo and in vitro. Deletion of the P2Y13 receptor leads to less trabecular bone in mice, by 245 
affecting both osteoblasts and osteoclasts. As a consequence, a lower bone apposition rate and bone 246 
formation rate were detected in 4 month old P2Y13R-/- female mice. The down-regulation of 247 
RhoA/ROCK I signalling and a reduced ratio of RANKL/OPG may be the possible molecular 248 
mechanisms causing these bone phenotype alterations. The lower bone remodelling activity and the 249 
apparent protection from OVX-induced bone loss in P2Y13R-/- mice suggest a possible new target for 250 
fighting bone diseases such as osteoporosis in the future.  251 
 252 
 253 
254 
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MATERIALS AND METHODS 255 
Mice 256 
The strain of P2Y13 receptor knockout (P2Y13R-/-) mouse was generated by classical homologous 257 
recombination in ES cells and aggregation with morulae as previously described (46). Briefly, the 258 
targeting of the P2ry13 gene was obtained by replacing a 1200 bp fragment containing the first non 259 
coding exon and the first 182 bp from the ATG starting coding sequence by a neomycin-resistance 260 
cassette. Male chimeras obtained from two different ES cells colonies were used to generate the 261 
P2Y13R-/- mouse strain. Targeting of the gene was confirmed by Southern blotting and RT-PCR. The 262 
P2Y13 mutation was crossed on C57BL/6J background for 10 generations. P2Y13R-/- and wild type 263 
(WT) mice were housed in the same environmentally controlled conditions with a 12hr light/dark 264 
cycle at 22°C. They were free to access 2018 Teklad Global 18% Protein Rodent Diet containing 1.01% 265 
Calcium (Harlan Laboratories, UK) and water ad libitum in sterile RB-3 cages. For bone phenotype 266 
investigations, female mice were euthanized at 16 week of age. For dynamic histomorphometry, mice 267 
were given intraperitoneal injections of calcein (30 mg/kg) 14 days and 2 days prior to being 268 
euthanized. Hind limbs were dissected free of attached soft tissue for bone phenotype investigation. 269 
The lengths of tibiae were measured from the lowest point of the distal end to the highest point of the 270 
proximal end using calibrated vernier callipers. All procedures complied with the UK Animals 271 
(Scientific Procedures) Act 1986 and were reviewed and approved by the local Research Ethics 272 
Committee of the University of Sheffield (Sheffield, UK).  273 
 274 
ȝ&7 275 
Right tibiae were dissected, fixed in 70% ethanol and scanned by 6N\6FDQ  GHVNWRS ȝ&7276 
6N\6FDQDWWKHUHVROXWLRQRIȝPIRUWKHWLELDSUR[LPDOHQGDQGȝPIRUWKHZKROHWLELD7KH277 
X-UD\ VRXUFH ZDV RSHUDWHG DW N9 DQG ȝ$ ZLWK D  DOXPLQLXP ILOWHU 7ZR-dimensional CT 278 
images were captured every 0.7o through 180o rotation of the bone and were then reconstructed by 279 
Skyscan NRecon software at threshold of 0.0-0.16 and 0.0-0.14 for tibia proximal end and whole tibia 280 
scan respectively. Region of interest (ROI) was selected and analyzed by Skyscan CTan software. For 281 
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the proximal tibia scan, trabecular morphometry was characterized by measuring structural 282 
parameters from a 1.0mm thick trabecular abundant region which is 0.2mm below the growth plate. 283 
The parameters included the Bone Mineral density (BMD), bone volume fraction (BV/TV), trabecular 284 
thickness (Tb.Th), and trabecular number (Tb.N). Cortical bone parameters, including cortical bone 285 
volume (Ct.BV), endosteal diameter (Es. Dm), and periosteal diameter (Ps. Dm), were quantified 286 
from a 1.0mm thick predominantly cortical region 1.0mm below the growth plate. 287 
 288 
Bone histomorphometry 289 
The left tibiae were fixed in 10% buffered formalin, decalcified in 14.3% EDTA for 28 days, and then 290 
embedded in paraffin wax. Sections were cut (at 3µm) using a Leica Microsystems Microtome and 291 
TRAP stained as described previously (47, 48). Briefly, sections were incubated in prewarmed 292 
Acetate-tartrate buffer (0.1M Sodium tartrate (Sigma) in 0.2M Acetate buffer (Sigma), pH5.2) at 37°C 293 
for 5 mins, followed by 30 mins incubation at 37°C in 20mg/mL Naphthol AS-BI phosphate (Sigma) 294 
/Dimethylformamide (Fisher) in Acetate-tartrate buffer. The sections were then incubated in Acetate-295 
tartrate buffer hexazotised pararosaniline solution, ULQVHG LQ ZDWHU DQG FRXQWHUVWDLQHG LQ *LOO¶V296 
haematoxylin. The number of osteoblasts (N.Ob/B.Pm) and the number of osteoclasts were 297 
determined on a 3mm length of endocortical surface and a 0.75 mm2 trabecular bone area, starting 298 
0.25mm from the growth plate and viewed on a DMRB microscope (Leica Microsystems)(47). For 299 
dynamic histomorphometry, right tibiae were dissected and fixed in 70% ethanol, followed by 300 
embedded into LR White resin (Taab Laboratory Equipment Ltd). Sections were cut at 10µm using a 301 
Leica Microsystems Microtome. Mineral apposition rate (MAR) and the bone formation rate 302 
(BFR/BS) were obtained using a DMRB microscope as described previously (47). All 303 
histomorphometric parameters were based on the report of the ASBMR Histomorphometry 304 
nomenclature (49) and were obtained using the Osteomeasure bone histomorphometry software 305 
(Osteometrics) 306 
 307 
Primary osteoblast isolation 308 
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Neonatal mouse calvariae (less than 72 hours old, 5-7 pups per culture) were dissected and the 309 
attached soft tissue was removed by digestion in 1mg/ml Collagenase 1A (Sigma) for 15 mins. 310 
Calvariae were then subjected to serial digestion in 1mg/mL Collagenase 1A for 30 mins; 0.25% 311 
Trypsin/EDTA (Gibco) for 30 mins; and 1mg/mL Collagenase 1A for 30 mins, at 37°C. All cells were 312 
harvested from the digestion suspensions and seeded into a T75 flask and cultured until confluent in 313 
'0(0*/87$0$;PHGLXPZLWKVRGLXPS\UXYDWH*LEFR8QLWVP/3HQLFLOOLQDQG314 
ȝJP/6WUHSWRP\FLQ*LEFRDQGIRHWDOFDOIVHUXP)&6*LEFR 315 
 316 
Proliferation Assay 317 
First passage primary osteoblast cells isolated from P2Y13R-/- and WT neonatal calvaria were seeded 318 
at a density of 5 x103 cells per well of a 96-well plate and cultured in '0(0 */87$0$;319 
PHGLXPZLWKVRGLXPS\UXYDWH8QLWVP/3HQLFLOOLQDQGȝJP/6WUHSWRP\FLQDQG)&6320 
for 5 days. On day 5, samples were examined by 3-(4,5-dimethylthiazol-2-yl) -5- (3-321 
carboxymethoxyphenyl) -2- (4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay (Promega) 322 
DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV7KH DEVRUEDQFH ZDV UHDG DW QP RQ D SpectraMax 323 
M5e Microplate Reader (Molecular Devices). 324 
 325 
Mineralization assay 326 
First passage primary osteoblast cells were initially seeded at 1.5 x 104 cell/well in 12-well plate and 327 
cultured in growth medium for six days and changed into differentiation medium: DMEM© 328 
*/87$0$;ZLWKVRGLXPS\UXYDWH8QLWVP/3HQLFLOOLQDQGȝJP/6WUHSWRP\FLQ329 
)HWDOFDOIVHUXPQ0'H[DPHWKDVRQH6LJPDȝJP//-$VFRUEDWH$FLG6LJPDDQGP0ȕ-330 
glycerophosphate (Sigma)(50, 51). Cells were cultured in differentiation medium for three weeks and 331 
medium was changed every two to three days. Cells were then rinsed by PBS and fixed in 100% 332 
Ethanol for minimum 1 hr or maximum overnight at 4°C. Nodules formed by osteoblast were stained 333 
by Alizarin Red S (52). Briefly, cells after fixation were rinsed twice by PBS and incubated in 40mM 334 
alizarin red S pH 4.2 (Sigma) for 1hr at room temperature. Plates were washed with 95% ethanol on 335 
the shaker until solution became clear and air dried. The plates were then scanned using an Epson 336 
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Perfection 4990 Photo flatbed scanner (Epson Ltd, Herts, UK) and the percentage mineralisation area 337 
to the total area (Area Friction) was determined using Image J software (http://rsbweb.nih.gov/ij/). To 338 
normalize the results, the plates were re-hydrated using PBS and counterstained for 10-15 Sec with 339 
0.1% Toluidine blue. The plates were scanned and the total areas covered by cells were quantified 340 
using Image J software. The mineralization results were then normalized to the Toluidine blue 341 
staining results of their relevant wells. 342 
 343 
Primary Osteoclast isolation 344 
Osteoclasts were derived from the mononuclear hematopoietic cell population from the long bone 345 
marrow of 10 weeks old female mice. Mononuclear cells were isolated using a modified protocol to 346 
that previously described (53). In brief, the bone marrow of limbs was flushed out by PBS using a 347 
syringe with 25-gauge needle. Cells were harvested by centrifugation and resuspended in the selection 348 
medium (Alpha-0LQLPDO HVVHQWLDO PHGLXP Į 0(0 + */87$0$; Gibco), 100 Units/mL 349 
3HQLFLOOLQȝJP/6WUHSWRP\FLQ)&6DQGQJPOmurine macrophage colony stimulating 350 
factor (M-CSF). The cells were then transferred into a T75 flask and incubated for 24 hours at 37qC, 5% 351 
CO2 to allow the attachment of stromal cells. Non-adherent cells were collected by centrifugation and 352 
UHVXVSHQGHG LQ JURZWK PHGLXP Į 0(0*/87$0$; FRQWDLQLQJ  8QLWVP/ 3HQLFLOOLQ DQG353 
ȝJP/6WUHSWRP\FLQ)&6QJPOM-CSF, and 3ng/ml murine receptor activator of NF-354 
ț%OLJDQG5$1./) (R&D System)). The cells were then seeded onto glass coverslips ((Richardson's 355 
of Leicester) or dentine disks (www.dentinedisks.com) in 96-well plates at density of 1x106 cells per 356 
well and cultured at 37°C, 7% CO2 with the medium being replaced every 2-3 days. Cells on 357 
coverslips were cultured for 10 days and fixed in ice cold 10% buffered formalin, whereas cells on 358 
dentine disks were cultured for 17 days to allow time for resorption. Both coverslips and dentine disks 359 
were TRAP stained and counterstained E\*LOO¶VKDHPDWR[\OLQDVGHVFULEHGDbove (47). On coverslips, 360 
TRAP positive cells with more than 3 nuclei were quantified as osteoclasts. On dentine disks, the 361 
number of resorbing osteoclasts (defined as a TRAP positive cell in or in close proximity to resorption 362 
pits) and the amount of resorption per dentine disk were quantified by point-counting as previously 363 
described (54, 55). 364 
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 365 
TaqMan® Custom Array  366 
Total RNA was isolated from both primary osteoblasts and long bone marrow with TRI Reagent 367 
6LJPDDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQ([WUDFWHG51$ZDVTXDQWLILHGXVLQJD1DQR'URS368 
ND-1000 Spectophotometer (The Thermo Scientific) and RNA quality was checked using an Agilent 369 
2100 Bioanalyzer (Agilent Technologies). The cDNA was then synthesized using Promega ImProm-370 
,,UHYHUVHWUDQFULSWDVH3URPHJDZLWK2OLJRG7SULPHU3URPHJDDFFRUGLQJWRPDQXIDFWXUHU¶V371 
instruction. An Applied Biosystems TaqMan custom array was used to validate the differential 372 
expression of candidate genes. The quantitative RT-PCR amplification of the TaqMan arrays were 373 
performed on an Applied Biosystems 7900HT Real-Time PCR system (Applied Biosystems) with 374 
thermal cycling conditions: 2 mins at 50qC, 10 mins at 94.5qC, followed by 40 cycles of denaturation 375 
at 97qC for 30 sec and extension at 59.7qC for 1 min (56). Data was collected and analysed using the 376 
Applied Biosystems SDS 2.2.1 software (Applied Biosystems). In order to systematically compare all 377 
target genes and limit interpolated errors, the same threshold values of 0.2 was used for each gene. 378 
The data were then analyzed using the CT relative quantification method (33). Quantification of the 379 
target cDNAs in all samples was normalized to the endogenous control gene: ȕ-actin (Actb¨&7 380 
CTtarget ± CTActb). The difference in expression for each target cDNA between the WT and P2Y13R-/- 381 
PLFH ZDV H[SUHVVHG DV¨¨&7 ¨¨&7  ¨&7WT - ¨&7 P2Y13R-/-). Fold changes in target genes were 382 
FDOFXODWHG E\ WDNLQJ  WR WKH SRZHU RI WKH ¨¨&7 ¨¨CT). Any genes with more than two folds 383 
expression changes were recognized as significant variance (57). A heatmap showing gene expression 384 
pattern variance was built from QRUPDOL]HG ¨¨&7 YDOXHV, usinJ WKH µ*HQH3DWWHUQ¶ ZHE VRIWZDUH385 
(http://www.broadinstitute.org). Each colour patch in the heatmap represents the relative gene 386 
expression level, with a continuum of expression levels from dark blue (lowest) to bright red (highest). 387 
 388 
OVX surgery 389 
OVX or sham-OVX (SHAM) surgery was performed on 16 weeks old, virgin, female WT and 390 
P2Y13R-/- mice (n = 7-9/group). OVX and SHAM surgery were performed as previously described 391 
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(58). Briefly, mice were anesthetized with 1.5-4% isoflurane in oxygen for surgery. The back of each 392 
mouse was shaved and surrounding area was cleaned with 70% ethanol. Dorsal incision was made 393 
through the skin in the region between the dorsal hump and the base of the tail. The ovaries, 394 
surrounding ovarian fat pad, and part of uterine horns under the abdomen wall were removed. For 395 
sham surgery, the ovaries and proximal parts of the uterine horns were exteriorised briefly then 396 
returned to the abdominal cavity before wound closure. Mice were euthanized for bone phenotype 397 
examination 4 weeks and 12 weeks after surgery to investigate bone phenotype changes. 398 
 399 
Statistic analysis 400 
All data are expressed as mean ± SEM. Statistical significance was tested for using either univariate 401 
analysis of variance or an uQSDLUHG6WXGHQW¶V W-test using PASW Statistics (IBM, NY) and Prism 5 402 
software (GraphPad, La Jolla).  403 
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TABLE. 1. Quantitative results of tibia bone parameters by ȝCT analysis. 580 
 
WT 
n=8 
P2Y13R-/-  
n=7 
Means 
difference 
P value 
summary 
BMD (g/cm3) 1.15 ± 0.007 1.15 ± 0.010 Ĺ 
 
BV/TV 9.17 ± 0.340 5.73 ± 0.634 Ļ C 
BV (mm3) 0.15 ± 0.006 0.09 ± 0.010 Ļ C 
BS/BV (1/mm) 87.26 ± 1.428 91.14 ± 3.226 Ĺ 
 
Tb.Th (mm) 0.048 ± 0.0006 0.049 ± 0.0018 Ĺ 
 
Tb.N (1/mm) 1.89 ± 0.054 1.18 ± 0.132 Ļ C 
Tb.Pf (1/mm) 26.18 ± 0.992 31.81 ± 1.607 Ĺ B 
Tb.Sp (mm) 0.23 ± 0.003 0.33 ± 0.024 Ĺ C 
DA  2.49 ± 0.078 1.94 ± 0.051 Ę22.0% C 
SMI 2.13 ± 0.031 2.41 ± 0.074 Ĺ B 
Ct.BV (mm3) 0.83 ± 0.016 0.88 ± 0.029 Ĺ 
 
Es. Dm (mm) 1.29 ± 0.028 1.32 ± 0.018 Ĺ 
 
Ps.Dm (mm) 1.69 ± 0.029 1.71 ± 0.021 Ĺ 
 
 581 
Values are mean ± SEM 582 
b
   p 6WXGHQW¶VXQSDLUHGt-test) 583 
c
   p 6WXGHQW¶VXQSDLUHGt-test) 584 
 585 
 586 
587 
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List of Figure Legends 588 
FIG.1. P2Y13R-/- mice have reduced bone volume. 589 
(A) 3D models of whole tibiae from P2Y13R-/- and WT DQLPDOVZHUHFRQVWUXFWHGIURPȝ&7LPDJHV590 
No obvious morphological differences were found between the P2Y13R-/- and WT tibia, scale bar = 591 
2.0mm. (B) 3D models of the trabecular region of the tibiae ZHUHFRQVWUXFWHGIURPȝ&7LPDJHVVFDOH592 
bar = 0.5 mm. (C) ȝ&7GDWDDQDO\VLVVKRZHGP2Y13R-/- mice had 5.5% less total tibial bone volume, 593 
(D) 37.5% less trabecular bone volume, and (E) 37.8% fewer trabeculae than WT mice. All values are 594 
mean ± SEM, P2Y13R-/- n = 7, WT n = 8, c p 6WXGHQW¶VXQSDLUHGt-test). 595 
 596 
FIG.2. P2Y13R-/- mice have reduced numbers of osteoclasts and osteoblasts on the endocortical 597 
bone surface. 598 
Left tibiae were obtained from 16 week old female mice, sections prepared and TRAP stained as 599 
previously described (47). (A) Black arrows indicate TRAP positive osteoclasts on endocortical 600 
surface of both WT and P2Y13R-/- mice, scale bar = 50 µm. (B) P2Y13R-/- mice had 48.1% reduction in 601 
osteoclast numbers per mm endocortical surface (N.Oc/B.Pm = 2.8 ± 0.45 versus 5.4 ± 0.75, p = 602 
0.0136). (C) Cobblestone-like osteoblasts with large nuclei were also identified on endocortical 603 
surface and marked with black arrow heads, scale bar = 50 µm. (D) P2Y13R-/- mice had 42.6% 604 
decrease in osteoblast number per mm endocortical surface (N.Ob/B.Pm = 9.1 ± 1.47 versus 15.9 ± 605 
2.00, p = 0.0227) compared with WT controls. (E) TRAP positive osteoclasts (black arrowheads) and 606 
osteoblasts (black arrows) were identified on the trabecular surface of both WT and P2Y13R-/- mice, 607 
scale bar = 50 µm. (F) P2Y13R-/- mice had 22.9% decreased osteoblast numbers per mm trabecular 608 
bone surface (N.Ob/B.Pm = 13.5 ± 0.98 versus 17.4 ± 1.09, p = 0.0213). (G) There was no significant 609 
difference in osteoclast numbers on the trabecular bone surface (N.Oc/B.Pm =10.0 ± 1.39 versus 10.5 610 
± 0.47, p = 0.7587). All values are mean ± SEM, n = 6, a p < 0.05, b p 6WXGHQW¶VXQSDLUHGt-611 
test). 612 
 613 
FIG.3. P2Y13R-/- mice have reduced rates of bone formation in vivo 614 
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For dynamic histomorphometry, 16 weeks-old mice were given intraperitoneal injections of calcein 615 
(30 mg/kg) 14 days and 2 days prior to being euthanized. Right tibiae were obtained and LR White 616 
resin sections prepared. (A) First calcein label (white arrowheads) and second calcein label (white 617 
arrows) were both detected on the endocortical bone surface from both WT and P2Y13R-/- mice. The 618 
average width between the labels (W) were measured and used to calculate mineral apposition rate. M: 619 
bone marrow; Ct: cortical bone; scale bar = 5ȝP(B) Mineral apposition rate was 49.7% less on the 620 
endocortical bone surface of P2Y13R-/- mice tibia compared to WT (MAR = 1.53 ± 0.060 versus 3.03 621 
± 0.194, p < 0.0001). (C) Bone formation rate of P2Y13R-/- mice was significantly decreased by 48.9% 622 
compared to WT (BFR = 1.09 ± 0.047 versus 2.13 ± 0.167, p < 0.0001). All values are mean ± SEM, 623 
n = 6, c p 6WXGHQW¶VXQSDLUHGt-test). 624 
 625 
FIG.4. P2Y13R-/- mice have reduced osteoblast function and osteoclast formation in vitro due to 626 
altered expressions of key bone remodelling related genes 627 
(A) Primary osteoblast cells isolated from neonatal mice calvariae of both WT and P2Y13R-/- mice 628 
show no significant difference in proliferation.  (B) P2Y13R-/- osteoblasts showed a 50.1% reduction in 629 
mineralized area compared to osteoblasts from WT mice. (C) Representative whole well images of 630 
primary osteoblast cells cultured in differentiation medium for three weeks and stained with alizarin 631 
red S solution to reveal mineralisation, scale bar = 5.0 mm. All values are mean ± SEM, n = 3 repeat 632 
experiments with 12 replicates per experiment, c p < 0.001, (Univariate analysis of variance). (D+E) 633 
The number of osteoclasts (defined as TRAP positive cells (pink coloured) with three or more nuclei, 634 
black arrows), derived from M-CSF and RANKL treated P2Y13R-/- mice bone marrow and cultured on 635 
glass coverslips, was 49.5% less than that from WT, scale bar = 5ȝP. (F+G) There were 47.1% 636 
fewer resorbing osteoclasts [identified as TRAP positive cells (black arrows) in or in close proximity 637 
to resorption pits (white arrows)] formed from P2Y13R-/- mice, scale bar = 10ȝP. (H) This led to 638 
66.1% less resorption on the dentine disks compared to WT osteoclasts. (I) There was no significant 639 
difference in the amount of resorption per resorbing osteoclast, p = 0.4959. All values are mean ± 640 
SEM, n = 4, each repeat contains 6 replicates, c p   6WXGHQW¶V XQSDLUHG t-test). (J+K) The 641 
relative gene expression pattern variance was shown in a heatmap of QRUPDOL]HG¨¨&7YDOXHV from 642 
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TaqMan custom array; each colour patch in the heatmap represents the relative gene expression level, 643 
with a continuum of expression levels from dark blue (lowest) to bright red (highest). Compared to 644 
WT primary osteoblasts, the expression of RhoA in P2Y13R-/- osteoblasts was significantly down-645 
regulated while Tnfrsf11b (the gene for OPG) was up-regulated. Mapk3, Rock1, RhoA, and Tnfsf11 646 
(the gene for RANKL) were significantly down-regulation in P2Y13R-/- bone marrow samples 647 
compared to WT. No other key regulatory genes had changes in expression levels.  648 
 649 
FIG.5. P2Y13R-/- mice have a reduced estrogen deficiency-induced bone loss 650 
OVX surgery was performed on 16 week-old WT and P2Y13R-/- mice. Mice were euthanized 4 and 12 651 
weeks after surgery and right tibiae were isolated and examined using ȝ&7 6N\VFDQ 1172). The 652 
response of P2Y13R-/- mice to OVX was different for both BMD and trabecular thickness compared 653 
with WT at both time points. (A) WT mice had a significant reduction in BMD 4 weeks and 12 weeks 654 
after surgery, no significant reduction in BMD was observed in P2Y13R-/- mice at 4 weeks and a 655 
significant increase was observed at 12 weeks. (B) Trabecular thickness significantly decreased in 656 
WT mice both at 4 and 12 weeks after surgery, no significant reduction in thickness was observed in 657 
P2Y13R-/- mice at 4 weeks and an increase was observed at 12 weeks. All values are mean ± SEM, n = 658 
7-9, * p < 0.05 cf WT, *** p < 0.0001 cf WT; a p < 0.05 cf baseline, c p < 0.0001 cf EDVHOLQH6WXGHQW¶V659 
unpaired t-test). 660 
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